Solaxa
Solaxa Inc. is a Bethesda-based clinical-stage biopharmaceutical company developing proprietary aminopyridine drugs, led by SLX-100 for spinocerebellar ataxia type 27B (SCA27B), with commercialization rights out-licensed to Alvogen via a $95 million agreement.
- Company typePrivate
- Founded2021
- HeadquartersBethesda, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Solaxa does
Solaxa Inc. is a clinical-stage biopharmaceutical company founded in 2021 (originally as Peripheral Therapeutics Inc.) and headquartered in Bethesda, Maryland, operating as a Delaware Public Benefit Corporation. It is developing proprietary reformulations of aminopyridine ion-channel modulators to detect and treat nerve dysfunction, with a lead asset SLX-100 — a uniquely formulated dalfampridine (4-aminopyridine) — being advanced for spinocerebellar ataxia type 27B (SCA27B), a rare neurodegenerative disease with no FDA-approved therapies. The underlying science originates from co-founders Mark Noble (University of Rochester, founding scientific advisor to Acorda Therapeutics) and John Elfar (University of Arizona), and the broader aminopyridine platform is also being explored for traumatic peripheral nerve injury diagnosis and chemotherapy-induced neuropathy.
Solaxa operates in a capital- and partnership-intensive model typical of rare-disease biotech. It has secured FDA Orphan Drug Designation for 4-aminopyridine in SCA (7-year market exclusivity upon approval), FDA IND clearance via the Section 505(b)(2) pathway, and a registrational Phase 3 trial funded in part by a $7.3 million Congressionally Directed Medical Research Program grant. Its go-to-market strategy is asset-centric and out-licensed: in February 2026 it signed a $95 million global licensing agreement with Alvogen for SLX-100 in SCA27B, under which Alvogen (via its Almatica CNS subsidiary) handles worldwide commercialization while Solaxa retains regulatory sponsorship and is eligible for upfront, development, regulatory, and sales milestone payments plus double-digit royalties. Direct revenue from product sales is not contemplated; revenue mechanics are licensing, milestone, and royalty income.
Funding to date has been modest but strategically staged: a $670,000 round (May 2024), a $500,000 TEDCO/SSBCI investment (July 2024), and non-dilutive grant funding channeled through academic partners such as UCLA and Penn State. Leadership has been built out with Kerry Clem (formerly CCO of Acorda, now CEO), Amy Chappell, MD, FAAN as CMO (ex-Eli Lilly), Luis Gutierrez as COO, and Pete Zaudtke as Head of Business Development, alongside founder Christian Walker. Headcount is reported at 1-10, consistent with a lean clinical-stage operation that outsources clinical execution and, post-Alvogen, commercialization.
Solaxa firmographics
Firmographics- Name
- Solaxa
- Legal name
- Solaxa Inc.
- Website
- https://solaxa.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Solaxa Inc. is a Bethesda-based clinical-stage biopharmaceutical company developing proprietary aminopyridine drugs, led by SLX-100 for spinocerebellar ataxia type 27B (SCA27B), with commercialization rights out-licensed to Alvogen via a $95 million agreement.
- Ownership category
- akta.pro rank
Solaxa industry classification
Industry- Product category
- Rare Disease Neurology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Solaxa is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Solaxa business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing and Milestone Payments: Solaxa receives upfront payments, development milestones, regulatory milestones, and sales-based milestone payments from partners. The Alvogen agreement provides for an upfront payment plus up to $95 million in aggregate milestone payments, plus double-digit royalties on net sales.
- Drug Development and Commercialization: Pre-commercial clinical stage company developing proprietary formulations of aminopyridine drugs. Revenue expected from future product sales following FDA approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Solaxa product offering
Product offeringCore offering
Solaxa develops proprietary aminopyridine-based drug candidates — most notably SLX-100, a reformulated dalfampridine (4-aminopyridine) — to detect and treat nerve dysfunction in rare neurodegenerative and traumatic nerve disorders such as spinocerebellar ataxia type 27B (SCA27B), hereditary ataxias, peripheral nerve injury, and chemotherapy-induced peripheral neuropathy. The company advances these candidates through FDA clinical and regulatory milestones and monetizes them via out-licensing to commercial partners rather than direct sales.
Product overview
Solaxa is a clinical-stage biopharmaceutical company developing a focused portfolio of aminopyridine-based drugs that detect and treat ion channel dysfunction to restore nerve function. The company's primary product is SLX-100, a reformulated dalfampridine (4-aminopyridine) treatment for spinocerebellar ataxia type 27B (SCA27B) which achieved FDA IND clearance in January 2025 and entered Phase 3 clinical trials in March 2025. The pipeline targets hereditary ataxias, traumatic nerve injury, and chemotherapy-induced neuropathy. The company operates as a Public Benefit Corporation focused on developing accessible and impactful treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- SLX-100 SLX-100 is Solaxa's lead clinical-stage drug candidate — a proprietary reformulation of dalfampridine (4-aminopyridine) designed to modulate voltage-gated potassium ion channels and detect and treat nerve damage. It is being developed under the FDA Section 505(b)(2) pathway for spinocerebellar ataxia type 27B (SCA27B), a hereditary ataxia with no FDA-approved therapy, and is the subject of a $95M worldwide licensing deal with Alvogen (February 2026). The asset is intended for rare-disease neurology patients and is partnered to Alvogen's CNS-focused subsidiary Almatica for commercialization.
Quantifiable outcome
- Significant clinical improvement in gait, balance, and speech observed in patients with spinocerebellar ataxias
- +1 more outcomes
Companies that use Solaxa
Customer profileSegments2 records
Ideal customer profiles2 records
Solaxa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Solaxa partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- AlvogencoreGlobal license agreement for development and commercialization of SLX-100 for spinocerebellar ataxia type 27B. Alvogen acquires worldwide rights and will commercialize in U.S. through its Almatica CNS subsidiary and globally. Solaxa eligible for $95M in aggregate milestone payments plus double-digit royalties.
- University of California, Los Angeles (UCLA)corePartnership with Dr. Susan Perlman at UCLA for registrational clinical trial of SLX-100 for SCA27B. Funded by $7.3M Congressionally Directed Medical Research Program grant.
- National Ataxia FoundationcoreSponsored research agreement including participation in NAF's Drug Development Collaborative, sponsorship of CRC-SCA natural history study expansion to include SCA27B, and sponsorship of free genetic testing program for SCA27B diagnosis.
- Penn State College of Medicine / Penn State HealthcoreClinical trial collaboration evaluating 4-aminopyridine for diagnosing peripheral nerve injury type. Dr. John Elfar's team at CORTS conducting NIH-funded study to determine whether nerves are severed or crushed in trauma patients.
- University of RochestercoreFounding scientific collaboration with Mark Noble, Ph.D., Professor of Biomedical Genetics and Neuroscience at University of Rochester, who serves as CSO and Co-Founder. Technology based on discoveries from his lab.
- University of ArizonacoreFounding scientific collaboration with John Elfar, M.D., MBA, Professor and Chair of Orthopedics at University of Arizona, who serves as scientific advisor. His research on 4-AP for nerve injury diagnosis underlies company technology.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Solaxa competitors and assessment
Company assessmentDirect peers
- Acorda Therapeutics: Original developer of branded dalfampridine (Ampyra/4-AP) approved for MS walking impairment; the same active ingredient Solaxa is reformulating for SCA27B. Acorda's commercialization history underpins Solaxa's strategic playbook.
- Reata Pharmaceuticals: Rare neurology-focused biopharma developing therapies for serious neurological diseases, now part of Biogen. Comparable in clinical-stage development and orphan disease commercialization.
- Catalyst Pharmaceuticals: Specialty pharma focused on rare neurological and ophthalmic diseases with orphan-drug commercialization expertise. Comparable in targeting rare CNS indications with high unmet need.
- Harmony Biosciences: CNS-focused commercial-stage company that licensed and commercialized a neurology asset (Wakix). Comparable in licensing-driven model and rare neurology commercialization.
- Larimar Therapeutics: Clinical-stage biotech developing therapies for rare neurodegenerative diseases including Friedreich's ataxia. Direct comparator in rare ataxia/neurodegenerative space.
Emerging players
- Stoke Therapeutics: Clinical-stage company targeting severe genetic neurological diseases using antisense oligonucleotide technology. Overlaps in rare neurology with similar clinical-stage profile.
- Azafaros: Clinical-stage company developing treatments for rare lysosomal storage disorders with neurological involvement. Comparable as emerging rare neurology biotech.
- Aquestive Therapeutics: Specialty pharma with reformulation expertise in CNS indications via proprietary drug delivery platforms. Comparable to Solaxa's reformulation-driven 505(b)(2) strategy for CNS.
Broad incumbents
- Biohaven Pharmaceuticals: CNS-focused biopharma with broad neurology pipeline. Comparable as a CNS-focused specialty pharma that has successfully licensed and commercialized rare neurology assets.
- Sage Therapeutics: CNS-focused biopharma developing therapies for neurological and psychiatric disorders. Comparable as a broader CNS biopharma with orphan-drug experience and licensing-driven commercialization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Solaxa social profiles
Digital presenceSolaxa compliance and trust
Trust signalCompliance2 records
Solaxa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Solaxa leadership team
Management profileNumber of profiles
Profiles6 records
Solaxa funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Solaxa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Solaxa
What does Solaxa do?
Solaxa develops proprietary aminopyridine-based drug candidates — most notably SLX-100, a reformulated dalfampridine (4-aminopyridine) — to detect and treat nerve dysfunction in rare neurodegenerative and traumatic nerve disorders such as spinocerebellar ataxia type 27B (SCA27B), hereditary ataxias, peripheral nerve injury, and chemotherapy-induced peripheral neuropathy. The company advances these candidates through FDA clinical and regulatory milestones and monetizes them via out-licensing to commercial partners rather than direct sales.
Is Solaxa a public or private company?
Solaxa is a private company. It is classified as venture growth investor backed and is currently operating.
When was Solaxa founded?
Solaxa was founded in 2021. It employs 1 to 10 people.
Where is Solaxa based?
Solaxa is headquartered in Bethesda, United States, in the North America region.
How does Solaxa make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are drug Development and Commercialization.
Who are Solaxa's main competitors?
Direct peers on record are Acorda Therapeutics, Reata Pharmaceuticals, Catalyst Pharmaceuticals, Harmony Biosciences and Larimar Therapeutics. Emerging players are Stoke Therapeutics, Azafaros and Aquestive Therapeutics. Broad incumbents are Biohaven Pharmaceuticals and Sage Therapeutics.
Does Solaxa have an API?
No public API is recorded for Solaxa.
What industry is Solaxa in?
Solaxa's product category is Rare Disease Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.